Montis Biosciences Advances First-in-Class Dual-Action C1q Antibody with Strong Preclinical Proof-of-Concept in Neuroinflammatory Diseases
Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammation MB0109 demonstrated statistically significant disease-modifying activity in relevant in vivo models of demyelinating autoimmune diseases (EAN and EAE) Non-human primate PK/tox study showed favorable pharmacokinetics and excellent safety profile IND-enabling studies planned to […]